OncoPharm podcast

Paradigm and Daraxonrasib in NSCLC

2026-09-03
0:00
14:31
Spola tillbaka 15 sekunder
Spola framåt 15 sekunder
PARADIGM is finally published, so we have more details from this study presented at ASH about HMA/Ven vs. Intensive Chemo if fit patients with AML. Daraxonrasib looks like a promising drug for RAS-mutant NSCLC, too. Download the Oncology Learning Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

Fler avsnitt från "OncoPharm"